Alice announced that the FURVENT phase III trial of the company's product vometinib as a monotherapy for EGFR20 exon insertion mutation NSCLC did not reach the main research end point, that is, PFS assessed by BICR. Clinical benefits were observed at secondary endpoints such as PFS assessed by researchers and ORR by BICR. Although OS data is immature, there is an improvement trend. The safety characteristics were consistent with previous studies, and no new signals were found. The company is evaluating the full data set with ArriVent to determine next steps. As of September 30, 2026, the clinical trial invested a total of about 70.82 million yuan, which has been included in current profit and loss, and will not have a significant impact on current results.

Alice announced that the FURVENT phase III trial of the company's product vometinib as a monotherapy for EGFR20 exon insertion mutation NSCLC did not reach the main research end point, that is, PFS assessed by BICR. Clinical benefits were observed at secondary endpoints such as PFS assessed by researchers and ORR by BICR. Although OS data is immature, there is an improvement trend. The safety characteristics were consistent with previous studies, and no new signals were found. The company is evaluating the full data set with ArriVent to determine next steps. As of September 30, 2026, the clinical trial invested a total of about 70.82 million yuan, which has been included in current profit and loss, and will not have a significant impact on current results.